Richard Barry Buys 11,565 Shares of Cassava Sciences, Inc. (NASDAQ:SAVA) Stock

Cassava Sciences, Inc. (NASDAQ:SAVA – Get Rating) Director Richard Barry acquired 11,565 shares of Cassava Sciences stock in a transaction that occurred on Monday, March 6th. The stock was purchased at an average cost of $26.13 per share, for a total transaction of $302,193.45. Following the completion of the transaction, the director now directly owns 197,724 shares in the company, valued at $5,166,528.12. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Cassava Sciences Stock Performance

Shares of SAVA opened at $24.79 on Friday. The business’s fifty day moving average price is $28.78 and its 200 day moving average price is $32.82. Cassava Sciences, Inc. has a 12-month low of $13.84 and a 12-month high of $51.59.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on SAVA. Univest Sec decreased their target price on Cassava Sciences from $12.00 to $11.00 in a report on Tuesday, November 29th. HC Wainwright reissued a “buy” rating and set a $124.00 price target on shares of Cassava Sciences in a research report on Monday. Finally, B. Riley lowered their price objective on Cassava Sciences from $44.00 to $28.00 in a research report on Wednesday, January 25th.

Hedge Funds Weigh In On Cassava Sciences

Large investors have recently made changes to their positions in the company. Millennium Management LLC lifted its position in shares of Cassava Sciences by 130.9% during the fourth quarter. Millennium Management LLC now owns 20,902 shares of the company’s stock worth $617,000 after acquiring an additional 11,851 shares in the last quarter. Money Concepts Capital Corp bought a new position in Cassava Sciences during the 4th quarter valued at about $59,000. Norges Bank purchased a new stake in Cassava Sciences during the fourth quarter valued at approximately $9,749,000. Alps Advisors Inc. purchased a new stake in Cassava Sciences during the fourth quarter worth $836,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Cassava Sciences by 1.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 280,111 shares of the company’s stock worth $8,274,000 after buying an additional 5,173 shares in the last quarter. Institutional investors own 25.51% of the company’s stock.

Cassava Sciences Company Profile

(Get Rating)

Cassava Sciences, Inc engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.